IJCM  Vol.9 No.7 , July 2018
Reduction of Pain, Fatigue, Gastrointestinal and Other Symptoms and Improvement in Quality of Life Indicators in Fibromyalgia Patients with Membrane Lipid Replacement Glycerolphospholipids and Controlled-Release Caffeine
Abstract: Objectives: A preliminary, open label study was initiated to determine if oral wafers containing a combination of membrane glycerolphospholipids and controlled-release caffeine could reduce self-reported pain, fatigue, and gastrointestinal symptoms and improve quality of life (QOL) indicators in fibromyalgia patients. Methods: Pain, fatigue and other symptoms were determined using validated, patient survey forms completed over an 8-day test period and compared to baseline values. Participants included 21 patients (15 females and 6 males) of average age of 48.5 ± 9.8 years with a diagnosis of fibromyalgia. These patients consumed four daily chewable wafers containing glycerolphospholipids (4.8 g) and one controlled-released caffeine (184 mg) wafer that maintained caffeine levels at approximately one cup of coffee for over 8 h. Results: Participants in the study responded to the combination test supplement within days. By the end of the study there were significant overall improvements (36.1%, p < 0.001), reductions in pain (27.2%, p < 0.001), fatigue (37.8%, p < 0.001), gastrointestinal symptoms (54.7%, p < 0.001) and improved ability to complete tasks and participate in activities (quality of life indicators) (39.1%, p < 0.001). Regression analysis of the data using a generalized mixed-effects model and calculating R2 values indicated that reductions in pain, fatigue and gastrointestinal symptoms and improvements in quality of life indicators were consistent, and occurred with a low degree of variance. Males responded slightly better to the combination supplement than females but for most parameters these differences were not significant. Conclusions: The combination membrane lipid replacement glycerolphospholipid supplement with controlled-release caffeine was safe and effective and significantly reduced pain, fatigue and gastrointestinal symptoms as well as improved QOL indicators in fibromyalgia patients.
Cite this paper: Nicolson, G. , Settineri, R. , Ferreira, G. and Breeding, P. (2018) Reduction of Pain, Fatigue, Gastrointestinal and Other Symptoms and Improvement in Quality of Life Indicators in Fibromyalgia Patients with Membrane Lipid Replacement Glycerolphospholipids and Controlled-Release Caffeine. International Journal of Clinical Medicine, 9, 600-619. doi: 10.4236/ijcm.2018.97051.

[1]   Wolf, F., Clauw, D.J. and Fitzcharles, M.A. (2010) The American College of Rheumatology Preliminary Diagnostic Creiteria for Fibromyalgia and Measurement of Symptom Severity. Arthritis Care and Research, 62, 600-610.

[2]   Wolf, F., Clauw, D.J., Fitzcharles, M.A., Goldenberg, D.L., Häuser, W., Katz, R.S., Mease, P., Russell, A.S., Russell, I.J. and Winfield, J.B. (2011) Fibromyalgia Creiteria and Severity Scales for Clinical and Epidemiological Studies: A Modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. Journal of Rheumatology, 38, 1113-1122.

[3]   Breeding, P.C., Russell, N.C. and Nicolson, G.L. (2012) An Integrative Model of Chronically Activated Immune-Hormonal Pathways Important in the Generation of Fibromyalgia. British Journal of Medical Practitioners, 5, a524-a534.

[4]   Gran, J.T. (2003) The Epidemiology of Chronic Generalized Musculoskeletal Pain. Best Practice and Research in Clinical Rheumatology, 17, 547-561.

[5]   Chambers, D., Bagnall, A.-M., Hempel, S. and Forbes, C. (2006) Interventions for the Treatment, Management and Rehabilitation of Patients with Chronic Fatigue Syndrome/Myalgic Encepthalomyelitis: An Updated Systematic Review. Journal of the Royal Society of Medicine, 99, 506-520.

[6]   Reid, S., Chalder, T., Cleare, A., Hotopf, M. and Wessley, S. (2011) Chronic Fatigue Syndrome. BMJ Clinical Evidence, 2011, 1101.

[7]   Kroenke, K., Wood, D.R., Mangelsdorff, A.D., Meier, N.J. and Powell, J.B. (1988) Chronic Fatigue in Primary Care: Prevalence, Patient Characteristics, and Outcome. Journal of the American Medical Association, 260, 929-934.

[8]   Nicolson, G.L. (2016) Membrane Lipid Replacement: Clinical Studies Using a Natural Medicine Approach to Restoring Membrane Function and Improving Health. International Journal of Clinical Medicine, 7, 133-143.

[9]   Brand, M.D. and Nicholis, D.G. (2011) Assessing Mitochondrial Dysfunction in Cells. Biochemical Journal, 435, 297-312.

[10]   Halliwell, B. (1996) Oxidative Stress, Nutrition and Health, Experimental Strategies for Optimization of Nutritional Antoxidant Intake in Humans. Free Radical Research, 25, 57-74.

[11]   Duchen, M.R. and Szabadkai, G. (2010) Roles of Mitochondria in Human Disease. Essays in Biochemistry, 47, 115-137.

[12]   Montero, J., Mari, M., Colell, A., Morales, A., Basanez, G., Garcia-Ruiz, C. and Fernandez-Checa, J.C. (2010) Cholesterol and Peroxidized Cardiolipin in Mitochondrial Membrane Properties, Permeabilization and Death. Biochimica et Biophysica Acta, 797, 1217-1224.

[13]   Adibhatla, R.M. and Hatcher, J.F. (2010) Lipid Oxidation and Peroxidation in CNS Health and Disease: From Molecular Mechanisms to Therapeutic Opportunities. Antioxidants and Redox Signaling, 12, 125-169.

[14]   Nicolson, G.L. and Ash, M.E. (2014) Lipid Replacement Therapy: A Natural Medicine Approach to Replacing Damaged Phospholipids in Cellular Membranes and Organelles and Restoring Function. Biochimica et Biophysica Acta, 1838, 1657-1679.

[15]   Nicolson, G.L. and Ash, M.E. (2017) Membrane Lipid Replacement for Chronic Illnesses, Aging and Cancer Using Oral Glycerolphospholipid Formulations with Fructooligosaccharides to Restore Phospholipid Function in Cellular Membranes, Organelles, Cells and Tissues. Biochimica et Biophysica Acta, 1859, 1704-1724.

[16]   Nicolson, G.L., Rosenblatt, S., Ferreira de Mattos, G., Settineri, R., Breeding, P.C., Ellithorpe, R.R. and Ash, M.E. (2016) Clinical Uses of Membrane Lipid Replacement Supplements in Restoring Membrane Function and Reducing Fatigue in Chronic Diseases and Cancer. Discoveries, 4, e54. Nicolson.pdf

[17]   Scott, J.R., Hassett, A.L., Brummett, C.M., Clauw, D.J. and Harte, S.E. (2017) Caffeine as an Opioid Analgesic Adjuvant in Fibromyalgia. Journal of Pain Research, 10, 1801-1809.

[18]   McLellan, T.M., Caldwell, J.A. and Lieberman, H.R. (2016) A Review of Caffeine’s Effects on Cognitive, Physician and Occupational Performance. Neuroscience and Biobehavioral Reviews, 71, 294-312.

[19]   Doepker, C., Lieberman, H.R., Smith, A.P., Peck, J.D., El-Sohemy, A. and Welsh, B.T. (2016) Caffeine: Friend or Foe? Annual Review of Food Science and Technology, 7, 117-137.

[20]   Kerns, R.D., Turk, D.C. and Rudy, T.E. (1985) The West Haven-Yale Multidimensional Pain Inventory (WHYMPI). Pain, 23, 345-356.

[21]   Hann, D.M., Denniston, M.M. and Baker, F. (2000) Measurement of Fatigue in Cancer Patients: Further Validation of the Fatigue Symptom Inventory. Quality of Life Research, 9, 847-854.

[22]   Van Zanten, S.J.V., Talley, N.J., Bytzer, P., Klein, K.B., Whorwell, P.J. and Zinmeister, A.R. (1999) Design of Treatment Trials for Functional Gastrointestinal Disorders. Gut, 45, 69-77.

[23]   Bennett, R., Friend, R., Jones, K.D., Ward, R., Han, B.K. and Ross, R.L. (2009) The Revised Fibromyalgia Impact Questionnaire (FIQR): Validation and Psychometric Properties. Arthritis Research and Therapy, 11, R120.

[24]   Adam, B., Liebregts, T., Saadat-Gilani, K., Vinson, B. and Holtmann, G. (2005) Validation of the Gastrointestinal Symptom Score for the Assessment of Symptoms in Patients with Functional Dyspepsia. Alimentary Pharmacology and Therapy, 22, 357-363.

[25]   Nakagawal, S. and Schielzeth, H. (2013) A General and Simple Method for Obtaining R2 from Generalized Linear Mixed-Effects Models. Methods in Ecology and Evolution, 4, 133-142.

[26]   Ellithorpe, R.A., Settineri, R., Jacques, B. and Nicolson, G.L. (2012) Lipid Replacement Therapy Functional Food with NTFactor® for Reducing Weight, Girth, Body Mass, Appetite, Cravings for Foods and Fatigue while Improving Blood Lipid Profiles. Functional Foods in Health and Disease, 2, 11-24.

[27]   Nicolson, G.L. and Ellithrope, R.R. (2006) Lipid Replacement and Antioxidant Nutritional Therapy for Restoring Mitochondrial Function and Reducing Fatigue in Chronic Fatigue Syndrome and Other Fatiguing Illnesses. Journal of Chronic Fatigue Syndrome, 13, 57-68.

[28]   Seidman, M., Khan, M.J., Tang, W.X. and Quirk, W.S. (2002) Influence of Lecithin on Mitochondrial DNA and Age-Related Hearing Loss. Otolaryngology—Head and Neck Surgery, 127, 138-144.

[29]   Colodny, L., Lynch, K., Farber, C., Papish, S., Phillips, K., Sanchez, M., Cooper, K., Pickus, O., Palmer, D., Percy, T.B., Faroqui, M. and Block, J.B. (2000) Results of a Study to Evaluate the Use of Propax to Reduce Adverse Effects of Chemotherapy. Journal of the American Nutraceutical Association, 3, 17-25.

[30]   Nicolson, G.L. (2010) Lipid Replacement Therapy: A Nutraceutical Approach for Reducing Cancer-Associated Fatigue and the Adverse Effects of Cancer Therapy while Restoring Mitochondrial Function. Cancer and Metastasis Reviews, 29, 543-552.

[31]   Ellithorpe, R.R., Settineri, R. and Nicolson, G.L. (2003) Reduction of Fatigue by Use of a Dietary Supplement Containing Glycophospholipids. Journal of the American Nutraceutical Association, 6, 23-28.

[32]   Agadjanyan, M., Vasilevko, V., Ghochikyan, A., Berns, Kesslak, P., Settineri, R. and Nicolson, G.L. (2003) Nutritional Supplement (NTFactor) Restores Mitochondrial Function and Reduces Moderately Severe Fatigue in Aged Subjects. Journal of Chronic Fatigue Syndrome, 11(3), 23-36.

[33]   Ellithorpe, R., Settineri, R., Mitchell, C., Jacques, B., Ellithorpe, T. and Nicolson, G.L. (2011) Lipid Replacement Therapy Drink Containing a Glycophospholipid Formulation Rapidly and Significantly Reduces Fatigue While Improving Energy and Mental Clarity. Functional Foods in Health and Disease, 1, 245-254.

[34]   Laska, E.M., Sunshine, A., Mueller, F., et al. (1984) Caffeine as an Analgesic Adjuvant. Journal of the American Medical Association, 251, 1711-1718.

[35]   Vaerøy, H., Abrahamsen, A., Forre, Ø. and Kåss, E. (1989) Treatment of Fibromyalgia (Fibrositis Syndrome): A Parallel Double Blind Trial with Carisoprodol, Paracetamol and Caffeine (Somadril Comp) versus Placebo. Clinical Rheumatology, 8, 245-250.

[36]   Jahan, F., Nanji, K., Qidwai, W. and Qasim, R. (2012) Fibromyalgia Syndrome: An Overview of Pathophysiology, Diagnosis and Management. Oman Medical Journal, 27, 192-195.

[37]   Bellato, E., Marina, E., Castoldi, F., Barbasetti, N., Mattei, L., Bonasina, D.E. and Blonna, D. (2012) Fibromyalgia Syndrome: Etiology, Pathogenesis, Diagnosis, and Treatment. Pain Research and Treatment, 2012, Article ID: 426130.

[38]   Lund-Olesen, L.H. and Lund-Olesen, K. (1994) The Etiology and Possible Treatment of Chronic Fatigue Syndrome/Fibromyalgia. Medical Hypotheses, 43, 55-58.

[39]   Green, H.J., Ranney, D., Burnett, M., Galvin, P., et al. (2014) Excitation-Contraction Coupling Properties in Women with Work-Related Myalgia: A Preliminary Study. Canadian Journal of Physiology and Pharmacology, 92, 498-506.

[40]   Stephenson, D.G. (2008) Caffeine—A Valuable Tool in Excitation-Contraction Coupling Research. Journal of Physiology, 586, 695-696.

[41]   Tsai, T.D. and Barish, M.E. (1995) Imaging of Caffeine-Inducible Release of Intracellular Calcium in Cultured Embryonic Mouse Telencephalic Neurons. Developmental Neurobiology, 27, 252-265.

[42]   Ferreira, G., Costa, C., Bassaizteguy, V., Santos, M., Cardozo, R., Montes, J., Settineri, R. and Nicolson, G.L. (2018) Incubation of Human Sperm with Micelles Made from Glycerophospholipid Mixtures Increases Sperm Motility and Resistance to Oxidative Stress. PLoS ONE, 13, e0197897.